Browsing by Author "Du, Ming-Qing"
Now showing items 2-7 of 7
-
Diffuse large B-cell lymphoma: sub-classification by massive parallel quantitative RT-PCR
(Nature Publishing Group, 2014-11-24)Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous entity with remarkably variable clinical outcome. Gene expression profiling (GEP) classifies DLBCL into activated B-cell like (ABC), germinal centre B-cell like (GCB) ... -
Identification of novel prognostic markers in cervical intraepithelial neoplasia using LDMAS (LOH Data Management and Analysis Software)
(2005-01-26)Abstract Background Detection of Loss of Heterozygosity (LOH) is one of the most common molecular applications in the study of human diseases, in particular cancer. The technique is commonly used to examine whether a known ... -
KLF2 mutation is the most frequent somatic change in splenic marginal zone lymphoma and identifies a subset with distinct genotype
(Nature Publishing Group, 2014-11-27)To characterise the genetics of splenic marginal zone lymphoma (SMZL), we performed whole exome sequencing of 16 cases and identified novel recurrent inactivating mutations in KLF2, a gene whose deficiency was previously ... -
The Prognosis of MYC Translocation Positive Diffuse Large B-Cell Lymphoma Depends on The Second Hit
(Wiley, 2015-01-08)A proportion of MYC translocation positive diffuse large B-cell lymphomas (DLBCL) harbour a BCL2 and/or BCL6 translocation, known as double-hit DLBCL, and are clinically aggressive. It is unknown whether there are other ... -
Somatic mutation screening using archival formalin-fixed paraffin-embedded tissues by Fluidigm multiplex PCR and Illumina sequencing
(Elsevier, 2015-07-09)High throughput somatic mutation screening using formalin-fixed paraffin-embedded (FFPE) tissues is a major challenge due to a lack of established methodology and validated variant calling algorithms. We aimed to develop ... -
The Mesenchymal Stem Cells in Multiple Sclerosis (MSCIMS) Trial protocol and baseline cohort characteristics: an open-label pre-test : post-test study with blinded outcome assessments
(2011-03-02)Abstract Background No treatments are currently available that slow, stop, or reverse disease progression in established multiple sclerosis (MS). The Mesenchymal Stem Cells in Multiple Sclerosis (MSCIMS) trial tests the ...
